Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib neoadjuvant therapy for locally advanced differentiated thyroid carcinoma
ChiCTR-OIC-17013425Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in thyroid cancer and well-differentiated thyroid cancer (WDTC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Oct 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR-OIC-17013425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17013425.